- [Resource Hub](/)
- [Field Guide](/?resource-type=field-guide#library)
- FFPE Nuclei Extraction for Neurodegenerative Disease Research

# FFPE Nuclei Extraction for Neurodegenerative Disease Research

The bottom line up front: Neurodegenerative disease research depends on FFPE brain tissue archives spanning decades of patient follow-up -- Alzheimer's cohorts, Parkinson's biobank specimens, ALS collections, and longitudinal aging studies. Manual nuclei extraction loses 50 to 60 percent of this irreplaceable tissue and selectively destroys the fragile neuronal populations that carry disease-relevant transcriptomic signatures. The Singulator 200+ automates the complete extraction workflow, preserving vulnerable neurons and delivering consistent results across disease stages, block ages, and multi-site consortia.

## The tissue that tells a twenty-year story

Somewhere in a brain bank freezer, there is an FFPE block from a patient enrolled in an Alzheimer's cohort in 2004. That patient was followed through annual cognitive assessments, amyloid PET imaging, CSF biomarker draws, and eventually autopsy. The block contains hippocampal tissue fixed at Braak stage V, and the clinical annotations attached to it represent two decades of longitudinal data that no prospective study could recreate.

Across the hall, another block holds substantia nigra from a Parkinson's patient whose dopaminergic neuron loss was documented over fifteen years of clinical visits. In a different building, a freezer holds frontal cortex sections from an ALS patient whose motor neuron degeneration progressed through three years of clinic records.

These blocks are not just tissue. They are the physical substrate of irreplaceable clinical narratives. And the method used to extract nuclei from them determines whether those narratives contribute to our understanding of neurodegeneration or become another set of failed preps in a lab notebook.

This guide covers specific strategies for processing FFPE brain tissue from neurodegenerative disease archives on the Singulator 200+, with attention to the challenges that make this work distinct from general FFPE processing: disease staging across Braak and other classification systems, longitudinal cohort comparisons spanning years of processing, cell-type vulnerability patterns where the neurons dying from disease are the same ones killed by harsh extraction, and the multi-site consortium reproducibility that programs like ADNI and AMP-AD require.

### TL;DR -- Neurodegenerative disease FFPE essentials

- Disease-stage comparisons (Braak I vs. VI, early vs. late Parkinson's) require identical processing -- the S200+ delivers 1.0M/1.0M replicate consistency

- Fragile neuronal nuclei lost to manual processing are the same populations carrying disease signatures

- Blocks archived 10, 20, or 30+ years still yield usable nuclei -- probe-based sequencing handles degraded RNA

- Multi-site consortia (ADNI, ROSMAP, AMP-AD) need operator-independent results that manual methods cannot guarantee

- The two-cartridge workflow processes inputs as small as a single section from a brain bank allocation

## Extract the biology that neurodegeneration is trying to teach you

Five deep-dive topics covering the specific challenges of working with FFPE brain tissue from neurodegenerative disease archives, from disease staging through multi-site consortium reproducibility.

Process tissue across disease stages
Process FFPE brain tissue across neurodegenerative disease stages

+

Neurodegenerative disease research often requires comparing tissue from different disease stages within the same cohort. An Alzheimer's study may need hippocampal sections from Braak stage I (preclinical) through Braak stage VI (severe). A Parkinson's study may compare substantia nigra from patients with early motor symptoms to those with advanced disease. The scientific question is straightforward: which cell types change, and how, as disease progresses? But the sample prep cannot be allowed to introduce its own variability on top of the biological differences.

### Why disease-stage comparisons are uniquely demanding

When you compare a Braak I section to a Braak VI section, any difference in the data should reflect disease biology -- not processing artifacts. Manual methods introduce variability at every step. If the Braak I section was processed by one technician on a Tuesday and the Braak VI section by a different technician three months later, the differences in deparaffinization timing, trituration force, and enzymatic incubation will create batch effects that overlap with the disease signal you are trying to measure. Computational correction can reduce these effects, but it cannot eliminate confounding that is systematically correlated with disease stage.

BATCH EFFECTS MIMIC BIOLOGY

If your Braak I samples were all processed in month one and your Braak VI samples in month six, any processing-related batch effect is perfectly correlated with disease stage. No amount of batch correction can separate a genuine disease signature from a systematic processing artifact when the two variables are confounded. The only solution is to eliminate the processing variability at the source.

### Staging systems and tissue selection

Different neurodegenerative diseases use different staging systems, and each system specifies distinct brain regions. Alzheimer's disease uses Braak staging for neurofibrillary tangles: entorhinal cortex in early stages, spreading to hippocampus and neocortex. Parkinson's uses Braak staging for alpha-synuclein pathology, progressing from brainstem to limbic to neocortical regions. Lewy body dementia overlaps with both. ALS has its own staging based on TDP-43 spread patterns. The brain region you section depends on the stage you are studying and the pathology you are tracking.

PRO TIP

When designing a disease-stage comparison study, select brain regions where the pathology is expected to be present at that stage, not regions where you hope it might be. Processing hippocampus from a Braak I patient looking for hippocampal tangles will likely show a normal transcriptomic profile -- the tangles have not reached the hippocampus yet. Work backward from the staging system to select the appropriate tissue.

### The FFPE two-cartridge workflow for disease staging studies

The Singulator 200+ processes each section through the same automated sequence: GREEN FFPE cartridge for deparaffinization, then YELLOW NIC+ cartridge for nuclei isolation. S200+ Only Every section receives identical mechanical force, identical enzymatic conditions, and identical timing. Whether you process the Braak I section today and the Braak VI section next month, the instrument removes the operator as a variable. Replicates yield 1.0 million and 1.0 million nuclei -- not the 1.5 million and 0.4 million variability seen with semi-automated methods.

Preserve the neurons disease is killing
Preserve the vulnerable neuronal populations that disease targets

+

The central irony of neurodegenerative disease research with FFPE tissue is that the neurons most relevant to your study are the ones most likely to be destroyed by your sample prep. Alzheimer's targets hippocampal pyramidal neurons. Parkinson's targets dopaminergic neurons in the substantia nigra. ALS attacks motor neurons in the spinal cord and motor cortex. These are large, morphologically complex cells with extensive processes and fragile nuclei -- and manual trituration kills them preferentially.

### Cell-type vulnerability maps to processing vulnerability

Neuronal nuclei are larger than glial or microglial nuclei. Hippocampal pyramidal neurons have nuclei measuring 10 to 15 micrometers in diameter, roughly twice the size of microglial nuclei. Larger nuclei are more susceptible to shear forces during mechanical dissociation. The vigorous pipetting required to break apart cross-linked FFPE tissue applies forces that exceed the structural integrity of these large neuronal nuclei, while smaller, denser microglial and oligodendrocyte nuclei survive. The result in your snRNA-seq data: microglial clusters dominate, neuronal clusters shrink, and the very cell populations undergoing disease-driven transcriptomic changes are underrepresented or absent.

CONTROLLED PROCESSING

The Singulator 200+ applies controlled, calibrated mechanical and enzymatic processing within sealed cartridges. The force is sufficient to dissociate cross-linked FFPE tissue but gentle enough to preserve large neuronal nuclei that manual trituration destroys. In comparable FFPE tissue studies, the S200+ enriched for fragile attached cell types that semi-automated methods lost, with semi-automated output skewing toward immune cells.

### What biased cell-type recovery means for disease studies

If your Alzheimer's hippocampal dataset shows abundant microglia but few excitatory neurons, you cannot distinguish whether the neurons are absent because the disease destroyed them or because the sample prep did. This ambiguity is fatal for disease-stage comparisons, where the entire point is to track neuronal loss and transcriptomic change across progression. A prep method that consistently loses neurons creates a floor effect -- every stage looks like late-stage disease because the neurons are gone from the data regardless of what happened in the tissue.

Compare your snRNA-seq cell-type proportions against published spatial transcriptomics data from the same brain region. Spatial methods analyze tissue in situ without dissociation, so they provide an unbiased reference for expected cell-type ratios. If your sequencing data shows far fewer neurons than the spatial reference, the extraction method is the likely bottleneck.

DO NOT CONFUSE PREP BIAS WITH DISEASE BIOLOGY

A dataset showing 80 percent microglia from hippocampal tissue may reflect genuine neuroinflammation -- or it may reflect a prep method that destroyed most neuronal nuclei. Without a reference for expected cell-type proportions, you cannot tell the difference. Use spatial data or published histological counts as your benchmark before drawing biological conclusions from cell-type ratios.

Compare longitudinal cohort tissue
Compare tissue processed months or years apart within the same cohort

+

Longitudinal neurodegenerative disease studies can span decades. The Religious Orders Study and Rush Memory and Aging Project (ROSMAP) has been collecting postmortem brain tissue since 1994. The Alzheimer's Disease Neuroimaging Initiative (ADNI) has followed patients through multiple waves of data collection. When these cohorts reach autopsy, the tissue arrives at the lab in waves -- not all at once. The first brains may be processed years before the last ones.

### The batch effect problem in long-running studies

Manual FFPE processing introduces variability at every step: deparaffinization timing, rehydration duration, trituration pressure, enzymatic incubation temperature. If your lab processes the first wave of ROSMAP tissue in 2024 with one technician and the second wave in 2027 with a different technician, the processing variability between waves may be larger than the biological differences between patients. Personnel change. People graduate, take new jobs, go on parental leave. The technician who developed excellent manual technique over two years is replaced by someone learning the protocol from a written SOP that describes "vigorous pipetting" without quantifying what vigorous means.

TIMELINE REALITY

A longitudinal Alzheimer's study may process tissue from the first autopsy in year one and the last autopsy in year ten. Manual protocols cannot guarantee consistent results across that span. The S200+ delivers 1.0M/1.0M replicate consistency whether the samples are processed on the same day or years apart, because the instrument applies identical mechanical force and enzymatic conditions regardless of when the button is pressed.

### What consistency actually means for your analysis

The Singulator 200+ reduces the processing workflow to 4 pipetting steps and less than 5 minutes of hands-on time. Compare that to the 28 pipetting steps and 25 minutes of hands-on time required by semi-automated methods. With fewer manual steps, there are fewer opportunities for human variability to enter the data. The 81 percent reduction in hands-on time is not about saving a technician twenty minutes -- it is about eliminating twenty minutes of potential batch effects from every sample in a multi-year cohort.

### Archival block quality across cohort timepoints

A long-running cohort means that the first blocks in the study may be significantly older than the last ones. A brain autopsied and fixed in 2005 has been sitting in paraffin for twenty years by the time you process it in 2025. A brain from 2023 has been archived for only two years. RNA quality (measured by DV200) typically declines with block age, but nuclei integrity is more resilient. The S200+ recovers intact nuclei from blocks of varying age. For RNA quality, run a DV200 check on a thin test section before committing your limited curls.

Block age
Expected DV200
Recommended platform

0-5 years
>50%
10x Flex (strong data quality)

5-15 years
30-50%
10x Flex (usable, reduced genes per cell)

15+ years
<30%
Spatial (Xenium) or targeted panels

PRO TIP

If your cohort spans blocks from 2000 to 2024, do not assume all blocks will perform equally. Group your samples by approximate block age and run a pilot DV200 from each age group before committing precious sections. This prevents investing a rare Braak VI section from 2002 into a Flex run when the RNA quality may be better suited for a spatial approach.

Standardize across consortium sites
Standardize processing across multi-site neurodegenerative disease consortia

+

Programs like ADNI, AMP-AD, the BRAIN Initiative Cell Census Network, and the Human Cell Atlas Brain Initiative distribute tissue and data across multiple institutions. The scientific value of these programs depends on comparability: data from Site A must be analyzable alongside data from Site B without site being a confounding variable. Manual FFPE processing makes this nearly impossible, because every site has its own technicians, its own interpretation of "vigorous trituration," and its own version of deparaffinization timing.

### Why multi-site studies break with manual processing

Consider a four-site Parkinson's consortium where each site receives substantia nigra sections from the same patient cohort. With manual protocols, Site A uses 20-minute deparaffinization, Site B uses overnight because their technician starts the protocol at 4 PM and processes the next morning. Site C has a postdoc who uses gentle trituration; Site D has a technician who pipettes forcefully. The resulting nuclei preparations differ in yield, cell-type composition, and debris levels -- not because the tissue differed, but because the people differed. When these datasets are merged, site-specific batch effects can mask or mimic disease biology.

OPERATOR-INDEPENDENT PROCESSING

The Singulator 200+ replaces operator-dependent manual steps with a fixed, automated workflow. The GREEN FFPE cartridge runs deparaffinization on-instrument with a proprietary safe solvent -- no fume hood required, which means any site can participate regardless of lab setup. The YELLOW NIC+ cartridge runs nuclei isolation with pre-installed protocols. Four pipetting steps. Less than 5 minutes hands-on. What remains for the human to vary is almost nothing.

### Practical deployment across sites

For a consortium deploying the S200+ across multiple institutions, the workflow is the same at every site: load tissue into GREEN cartridge, run deparaffinization, transfer to YELLOW NIC+ cartridge, run nuclei isolation, collect output. No site-specific protocol adaptations. No local deparaffinization timing preferences. No variability in trituration force. The instrument is the protocol, and the protocol is identical everywhere.

The elimination of toxic solvents (no xylene, no CitriSolv) removes a practical barrier to multi-site deployment. Sites without fume hoods or chemical waste disposal infrastructure can still run the FFPE workflow. This matters for smaller academic institutions or satellite facilities that might otherwise be excluded from a consortium because of facility limitations.

CONSORTIUM CONSISTENCY DATA

Share the replicate data with consortium leadership: S200+ replicates yield 1.0M and 1.0M nuclei versus 1.5M and 0.4M with semi-automated methods. That 3.75-fold improvement in consistency translates directly to reduced batch effects when merging data across sites. For an NIH-funded consortium, processing standardization is often an explicit review criterion.

Choose the right analytical platform
Choose the right analytical platform for your neurodegenerative disease question

+

The analytical platform you choose should match your scientific question, not the other way around. A study tracking transcriptomic changes in specific neuronal subtypes across Braak stages needs sequencing depth. A study mapping where pathology-associated cell types sit within brain architecture needs spatial resolution. Many studies need both. The Singulator 200+ produces platform-agnostic nuclei, which means you can design your analytical strategy based on the biology rather than the sample prep.

### 10x Genomics Flex for degraded archival tissue

The Flex assay is the default choice for snRNA-seq from neurodegenerative disease FFPE tissue. Its probe pairs have a compact 50-nucleotide footprint, bypassing the need for intact poly-A tails -- which is relevant for archival blocks where RNA degradation is expected. FFPE tissue from PDAC studies processed on the S200+ yielded 1,844 to 2,245 UMI counts per nucleus on Flex, demonstrating that the nuclei quality supports meaningful transcriptomic data even from fixed tissue. A single brain section processed on the S200+ typically yields over 1 million nuclei -- far exceeding the 10,000 to 20,000 needed for a Flex loading.

DISEASE-STAGE MULTIPLEXING

10x Flex supports sample multiplexing, which allows you to pool nuclei from multiple disease stages onto a single chip. Process each Braak stage section individually on the S200+, then pool the nuclei at known ratios before Flex loading. This approach reduces per-sample sequencing cost while enabling direct comparison of disease stages within the same sequencing run, minimizing technical batch effects between stages.

### Spatial transcriptomics for architectural context

Neurodegenerative diseases alter brain architecture -- amyloid plaques in Alzheimer's, Lewy bodies in Parkinson's, motor neuron loss patterns in ALS. Spatial platforms like 10x Xenium map these patterns in situ. Memorial Sloan Kettering's Dana Pe'er lab used S200+ nuclei alongside Xenium spatial analysis for brain tissue studies. For neurodegenerative disease research, consider sectioning adjacent sections from the same block: one for Xenium spatial analysis and one for S200+ nuclei extraction and snRNA-seq. The spatial data provides the map; the snRNA-seq provides the depth to annotate every cell type on that map.

### PERFF-seq for rare disease-specific populations

Some neurodegenerative disease questions target rare populations: disease-specific neuronal subtypes undergoing selective degeneration, infiltrating immune cells at disease boundaries, or reactive astrocyte subsets around plaques. PERFF-seq, validated by Stanford and Memorial Sloan Kettering, captures rare cells from FFPE tissue at depths that standard snRNA-seq cannot match. S200+ nuclei are validated for this workflow. When your question hinges on a cell population that constitutes less than 1 percent of the tissue, PERFF-seq maximizes the information you extract per nucleus.

DECIDE BEFORE YOU SECTION

For irreplaceable neurodegenerative disease tissue, commit to a platform before cutting the block. Each platform has different input requirements and different tolerance for debris and RNA quality. Discovering after extraction that your nuclei are insufficient for the intended platform means wasting tissue you cannot replace. Plan the analysis, then work backward to the section.

## Troubleshooting neurodegenerative disease FFPE challenges

Problem: snRNA-seq data from Alzheimer's hippocampus shows predominantly microglia with few neuronal clusters
Solution: This pattern often reflects processing bias rather than disease biology. Manual trituration preferentially destroys large, fragile neuronal nuclei while preserving smaller microglial nuclei. Compare your cell-type proportions against published spatial transcriptomics references for the same brain region and disease stage. If the spatial data shows neurons that your sequencing data lacks, the extraction method is the likely cause. The Singulator 200+ preserves neuronal nuclei through controlled mechanical processing that avoids the shear forces of manual pipetting.

Problem: DV200 values differ widely across blocks in the same longitudinal cohort
Solution: Variable DV200 within a cohort typically reflects differences in fixation conditions rather than disease stage. Brain banks that collected tissue over decades may have changed fixation protocols, or individual cases may have experienced different postmortem intervals before fixation. Group your samples by DV200 range and consider using different analytical approaches for different quality tiers: Flex for blocks above 30 percent DV200, spatial platforms for blocks below 30 percent. The S200+ recovers nuclei consistently regardless of RNA quality -- the nuclei yield is independent of the DV200 score.

Problem: Batch effects between consortium sites persist despite using the same manual protocol
Solution: "The same protocol" applied manually at different sites is not actually the same protocol. Deparaffinization timing, trituration intensity, and enzymatic incubation temperature vary by operator even when following identical written instructions. The S200+ eliminates this by automating the entire workflow with 4 pipetting steps and less than 5 minutes hands-on time. The instrument applies identical conditions at every site, removing operator interpretation from the equation. Share the replicate consistency data (1.0M/1.0M versus 1.5M/0.4M) with consortium coordinators when proposing standardization.

Problem: Brain tissue block from a 25-year-old Parkinson's cohort yields low nuclei count
Solution: Very old blocks can yield fewer nuclei due to progressive cross-linking and tissue desiccation over decades of storage. First, verify the tissue mass meets the 2 mg minimum. If the block has been heavily sectioned over the years, less tissue may remain than expected. For blocks with reduced yield, even 200,000 to 500,000 nuclei can support a 10x Flex experiment -- the loading requirement is 10,000 to 20,000 nuclei, so reduced yields are often still sufficient. If yield is genuinely low and additional sections are available, process a second section and pool the nuclei suspensions.

## Frequently asked questions

Can the Singulator 200+ process FFPE brain tissue from Alzheimer's cohorts archived for 20 or more years?

Yes. The Singulator 200+ recovers intact nuclei from FFPE blocks regardless of block age. RNA quality does decline in older blocks, but probe-based sequencing platforms like 10x Genomics Flex use probe pairs with a compact 50-nucleotide footprint, bypassing the need for intact poly-A tails. Run a DV200 quality check to set expectations: blocks above 50 percent DV200 typically yield strong data, 30 to 50 percent is usable with reduced gene detection, and below 30 percent may be better suited for spatial platforms that do not require dissociation.

How does automated processing preserve the vulnerable neuronal populations lost in manual Alzheimer's tissue prep?

Manual FFPE protocols use vigorous trituration that preferentially destroys large, fragile neuronal nuclei while leaving smaller, robust microglia and astrocytes intact. The Singulator 200+ applies controlled mechanical and enzymatic processing within sealed cartridges, calibrating force to preserve fragile cell types. Comparable FFPE studies showed the S200+ enriched for fragile attached populations while semi-automated methods skewed toward immune cells.

Is the Singulator 200+ suitable for processing tissue from multi-site neurodegenerative disease consortia like ADNI or AMP-AD?

Yes. Multi-site consortia need identical results from every site, every operator, every month. The S200+ eliminates operator variability through automated processing with 4 pipetting steps and less than 5 minutes of hands-on time. Replicates yield 1.0 million nuclei each, compared to the 1.5 million and 0.4 million variation seen with semi-automated methods. No fume hood is required, which means any participating site can run the protocol regardless of facility setup.

Can I compare disease-stage tissue from different Braak stages processed at different times?

Yes. The Singulator 200+ delivers consistent replicate yields of 1.0 million nuclei per curl regardless of when the sample is processed. A Braak stage I section processed in January produces comparable nuclei to a Braak stage VI section processed in July, provided the blocks have similar fixation histories. This consistency eliminates the batch effects that manual processing introduces between samples run months or years apart.

What downstream platforms work best for neurodegenerative disease FFPE tissue processed on the Singulator 200+?

10x Genomics Flex is the default for snRNA-seq from degraded FFPE tissue because its probe-based chemistry handles fragmented RNA. For spatial context, pair snRNA-seq data from S200+ nuclei with Xenium analysis on adjacent sections -- Memorial Sloan Kettering's Dana Pe'er lab used snRNA-seq from S200+ nuclei as companion data alongside Xenium spatial analysis. For rare disease-specific cell populations, PERFF-seq captures rare nuclei at depths standard snRNA-seq cannot match. The Singulator 200+ produces platform-agnostic nuclei validated for 10x Flex and PERFF-seq, with snRNA-seq data serving as companion to Xenium spatial analysis.

### Key takeaway

Neurodegenerative disease research depends on extracting meaningful data from FFPE brain tissue that was archived years or decades ago. Manual processing destroys the fragile neuronal populations that carry disease signatures, introduces batch effects that confound disease-stage comparisons, and produces results that vary between operators and sites. The Singulator 200+ gives researchers a consistent, automated path from archival block to sequencing-ready nuclei -- preserving the vulnerable neurons that neurodegeneration targets, delivering reproducible results across longitudinal cohorts, and standardizing processing for multi-site consortia that need every dataset to be comparable.

[Back to all resources](/#library)
## Similar resources
[Field Guide](/resources/brain-tissue-complexity-myelin-lipids-neuronal-nuclei/) Singulator 200+ 2026
### Overcoming Brain Tissue Complexity: Myelin, Lipids, and Fragile Neuronal Nuclei

Brain FFPE tissue creates unique nuclei isolation challenges. Myelin debris, lipid contamination, and fragile neuronal nuclei require controlled automated processing to preserve cell-type diversity for single-nucleus sequencing.
[Read Field Guide](/resources/brain-tissue-complexity-myelin-lipids-neuronal-nuclei/) [Field Guide](/resources/brain-tumor-ffpe-surgical-resection-single-cell/) Singulator 200+ 2026
### Brain Tumor FFPE Processing: From Surgical Resection to Single-Nucleus Insights

Process brain tumor FFPE from surgical resections on the Singulator 200+. Preserve cancer cells and immune populations for snRNA-seq and spatial analysis.
[Read Field Guide](/resources/brain-tumor-ffpe-surgical-resection-single-cell/) [Ebook](/resources/cold-case-files-neuroscience-ffpe/) Singulator 200+ 2026
### Cold Case Files:The Brain's Embedded Evidence

How the Singulator 200+ preserves fragile neuronal nuclei from irreplaceable postmortem brain tissue. Automated FFPE processing for Alzheimer's, brain tumors, and brain atlases.
[Read Ebook](/resources/cold-case-files-neuroscience-ffpe/) [Field Guide](/resources/integrating-snrna-seq-spatial-transcriptomics-brain-ffpe/) Singulator 200+ 2026
### Integrating snRNA-seq with spatial transcriptomics for brain mapping

Pair spatial transcriptomics with snRNA-seq from the same FFPE brain block. Block allocation, platform selection, and nuclei quality for multi-omic brain studies.
[Read Field Guide](/resources/integrating-snrna-seq-spatial-transcriptomics-brain-ffpe/) [Field Guide](/resources/maximizing-limited-brain-tissue-sections-ffpe/) Singulator 200+ 2026
### Maximizing Results from Limited Brain Tissue Sections

Get high-quality nuclei from limited postmortem brain FFPE sections. Process NIH biobank allocations, hospital archives, and surgical specimens on the Singulator 200+.
[Read Field Guide](/resources/maximizing-limited-brain-tissue-sections-ffpe/) [Field Guide](/resources/navigating-postmortem-brain-tissue-ffpe-genomics/) Singulator 200+ 2026
### Navigating postmortem brain tissue for FFPE genomics

Practical guide to postmortem brain FFPE challenges: necropsy timing, fixation variability, biobank sourcing, myelin debris, and how the Singulator 200+ standardizes nuclei extraction.
[Read Field Guide](/resources/navigating-postmortem-brain-tissue-ffpe-genomics/) [Field Guide](/resources/reproducible-multi-site-brain-tissue-atlases-singulator/) Singulator 200+ 2026
### Building Reproducible Multi-Site Brain Tissue Atlases

Standardize brain FFPE nuclei extraction across consortium sites with the Singulator 200+. Eliminate operator variability, prevent batch effects, and scale for atlas projects.
[Read Field Guide](/resources/reproducible-multi-site-brain-tissue-atlases-singulator/) [Ebook](/resources/tissue-dissociation-protocol-guide/) Singulator 100 Singulator 200 Singulator 200+ 2026
### Tissue Dissociation Guide

The most comprehensive tissue dissociation reference available. Interactive protocols for single-cell isolation and nuclei extraction across 57+ tissue types with community and Singulator-optimized methods.
[Read Ebook](/resources/tissue-dissociation-protocol-guide/) [Blog](/resources/cold-case-closed-brain-atlas/) Singulator 200+ 2026
### Cold Case - Part 5: Case Closed

Brain atlases are being built. Archival tissue is finally talking. How standardized nuclei extraction and platform-agnostic analysis are solving neuroscience's oldest cold cases.
[Read Blog](/resources/cold-case-closed-brain-atlas/) [Blog](/resources/cold-case-contaminated-evidence-brain-tissue/) Singulator 200+ 2026
### Cold Case - Part 2: Contaminated Evidence

Manual extraction of nuclei from FFPE brain tissue destroys 50 to 60 percent of starting material. Fragile neurons die first, leaving biased results. Here is what goes wrong.
[Read Blog](/resources/cold-case-contaminated-evidence-brain-tissue/) [Blog](/resources/cold-case-files-brain-tissue-evidence/) Singulator 200+ 2026
### Cold Case - Part 1: The Cold Case Files

Millions of FFPE brain tissue blocks sit in biobanks worldwide, holding decades of evidence about Alzheimer's, Parkinson's, and neurodegenerative diseases. What if we could reopen these cases?
[Read Blog](/resources/cold-case-files-brain-tissue-evidence/) [Blog](/resources/cold-case-forensic-lab-singulator-200-plus/) Singulator 200+ 2026
### Cold Case - Part 4: The Forensic Lab

Manual FFPE processing destroys fragile neuronal nuclei and produces variable results. The Singulator 200+ automates the workflow with a two-cartridge system that delivers consistent, operator-independent results from irreplaceable brain tissue.
[Read Blog](/resources/cold-case-forensic-lab-singulator-200-plus/)